Taken together, increased MEK/ERK and WNT activation in the quadruple-high subpopulation suggests that inhibiting these pathways may be clinically useful in targeting this highly clonogenic subset of glioma cells. This evidence concerns the gene MAP2K7 and central nervous system cancer.